相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells
Jiejie Dong et al.
PLOS ONE (2017)
Phase I trial of radiation therapy and sorafenib in unresectable liver metastases
Rebecca B. Goody et al.
RADIOTHERAPY AND ONCOLOGY (2017)
Local Radiotherapy Affects Drug PharmacokineticsExploration of a Neglected but Significant Uncertainty of Cancer Therapy
Yu-Jen Chen et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2017)
Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
Anthony M. Brade et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma
Daniel R. Wahl et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Improvement of Transmembrane Transport Mechanism Study of Imperatorin on P-Glycoprotein-Mediated Drug Transport
Zheng-Gen Liao et al.
MOLECULES (2016)
Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b
Aksana Vasilyeva et al.
CANCER RESEARCH (2015)
Phase 2 Study of Combined Sorafenib and Radiation Therapy in Patients With Advanced Hepatocellular Carcinoma
Shang-Wen Chen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Silymarin in Liposomes and Ethosomes: Pharmacokinetics and Tissue Distribution in Free-Moving Rats by High-Performance Liquid Chromatography-Tandem Mass Spectrometry
Li-Wen Chang et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2014)
Recall radiation dermatitis by sorafenib following stereotactic body radiation therapy
Chen-Hsi Hsieh et al.
ONCOTARGETS AND THERAPY (2014)
Reversing multidrug resistance in hepatocellular carcinoma cells by inhibiting extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway activity
Siyuan Chen et al.
ONCOLOGY LETTERS (2014)
Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway
Xiao-Fang Dai et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2013)
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin
Chen-Hsi Hsieh et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma
Aaron T. Wild et al.
PLOS ONE (2013)
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prognostic Factors of Local Control, Overall Survival, and Toxicity
Jean-Emmanuel Bibault et al.
PLOS ONE (2013)
High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma
Won Il Jang et al.
RADIATION ONCOLOGY (2013)
Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation
Hyung Gyun Kim et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment - case report
Chen-Hsi Hsieh et al.
BMC CANCER (2010)
Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics
Chen-Hsi Hsieh et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation
Jurjen S. Lagas et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters
Shuiying Hu et al.
CLINICAL CANCER RESEARCH (2009)
Combination of Sorafenib and Intensity Modulated Radiotherapy for Unresectable Hepatocellular Carcinoma
Chen-Hsi Hsieh et al.
CLINICAL DRUG INVESTIGATION (2009)
Sorafenib A Review of its Use in Advanced Hepatocellular Carcinoma
Gillian M. Keating et al.
DRUGS (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma
Zheng Wang et al.
CLINICAL CANCER RESEARCH (2008)
Dose translation from animal to human studies revisited
Shannon Reagan-Shaw et al.
FASEB JOURNAL (2008)
Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma
Regina V. Tse et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Targeting of p38 Mitogen-activated Protein Kinases to Early Growth Response gene 1 (EGR-1) in the Human Paclitaxel-resistance Ovarian Carcinoma Cells
Meisong Lu et al.
JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES (2008)
The nuclear factor-kappa B pathway regulates cytochrome P450 3A4 protein stability
R. C. Zangar et al.
MOLECULAR PHARMACOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cell cycle-dependent and schedule-dependent antitumor effects of sorafenib combined with radiation
John P. Plastaras et al.
CANCER RESEARCH (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Nuclear factor-κB p65 inhibits mitogen-activated protein kinase signaling pathway in radioresistant breast cancer cells
Kazi M. Ahmed et al.
MOLECULAR CANCER RESEARCH (2006)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics
C Lathia et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Management of hepatoceullular carcinoma
J Bruix et al.
HEPATOLOGY (2005)
In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats
M Kageyama et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2005)
Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-κB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis
F Thévenod et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Low-dose twice-daily fractionated X-irradiation of ovarian tumor cells in vitro generates drug-resistant cells overexpressing two multidrug resistance-associated proteins, P-glycoprotein and MRP1
BT Hill et al.
ANTI-CANCER DRUGS (2000)
分享论文
